A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Study sponsor: Arvinas Inc. · ARVN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-03-31Estimated
Enrollment · participants499Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.